STARC Spotlight: Skin Toxicities & Tumors in Pediatric Cancer Care

Skin reactions during pediatric cancer treatment can be painful, stigmatizing, and sometimes threaten a child’s ability to stay on therapy. In this episode of PeDRA Pearls, Dr. Christina Boull and Dr. Rebecca Levy discuss PeDRA's Skin Tumors and Reactions to Cancer Therapies (STARC) Focused Study Group and its work to prevent, recognize, and manage these toxicities. They highlight multicenter efforts spanning photosensitivity prevention, survivorship outcomes, and targeted therapy side effects—including MEK inhibitor–associated mucocutaneous toxicities—plus the need for stronger derm–onc collaboration, better trial reporting, and evidence-based consensus guidelines.Click here for more information.